SG10201506611XA - Posology and administration of glucocorticoid based compositions - Google Patents

Posology and administration of glucocorticoid based compositions

Info

Publication number
SG10201506611XA
SG10201506611XA SG10201506611XA SG10201506611XA SG10201506611XA SG 10201506611X A SG10201506611X A SG 10201506611XA SG 10201506611X A SG10201506611X A SG 10201506611XA SG 10201506611X A SG10201506611X A SG 10201506611XA SG 10201506611X A SG10201506611X A SG 10201506611XA
Authority
SG
Singapore
Prior art keywords
posology
administration
based compositions
glucocorticoid based
glucocorticoid
Prior art date
Application number
SG10201506611XA
Inventor
Thomas Hedner
Ulrika Sigrida Helena Simonsson
Gudmundur Johannsson
Hans Lennernäs
Stanko Skrtic
Original Assignee
Duocort Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42953726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201506611X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duocort Pharma Ab filed Critical Duocort Pharma Ab
Publication of SG10201506611XA publication Critical patent/SG10201506611XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
SG10201506611XA 2010-05-20 2011-05-18 Posology and administration of glucocorticoid based compositions SG10201506611XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201000442 2010-05-20

Publications (1)

Publication Number Publication Date
SG10201506611XA true SG10201506611XA (en) 2015-09-29

Family

ID=42953726

Family Applications (2)

Application Number Title Priority Date Filing Date
SG2012082129A SG185457A1 (en) 2010-05-20 2011-05-18 Posology and administration of glucocorticoid based compositions
SG10201506611XA SG10201506611XA (en) 2010-05-20 2011-05-18 Posology and administration of glucocorticoid based compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG2012082129A SG185457A1 (en) 2010-05-20 2011-05-18 Posology and administration of glucocorticoid based compositions

Country Status (15)

Country Link
US (2) US20130209565A1 (en)
EP (1) EP2571505B1 (en)
JP (1) JP2013526552A (en)
KR (1) KR20130099815A (en)
CN (1) CN102933218A (en)
AU (1) AU2011254959A1 (en)
BR (1) BR112012029466A2 (en)
CA (1) CA2799820A1 (en)
CL (1) CL2012003152A1 (en)
CO (1) CO6660433A2 (en)
IL (1) IL223000A0 (en)
MX (1) MX337429B (en)
PE (1) PE20131024A1 (en)
SG (2) SG185457A1 (en)
WO (1) WO2011144327A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401031D0 (en) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
US10262112B2 (en) * 2013-02-04 2019-04-16 Precera Bioscience, Inc. Prescription decision support system and method using comprehensive multiplex drug monitoring
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
ES2967617T3 (en) 2013-12-06 2024-05-03 Bioverativ Therapeutics Inc Population pharmacokinetics tools and their uses
WO2016196687A1 (en) * 2015-06-01 2016-12-08 Massachusetts Institute Of Technology System and method for neuroendocrine control
CN107115308B (en) * 2016-02-23 2021-02-23 天津金耀集团有限公司 Hydrocortisone biphasic sustained-release tablet composition
CN108553436A (en) * 2018-06-08 2018-09-21 华益药业科技(安徽)有限公司 A kind of 20mg hydrocortisones tablet recipe and technological procedure
WO2020037248A1 (en) * 2018-08-17 2020-02-20 The Regents Of The University Of California Diagnosing hypoadrenocorticism from hematologic and serum chemistry parameters using machine learning algorithm

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119848D0 (en) * 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
SE0401031D0 (en) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
NZ602010A (en) * 2009-04-07 2013-11-29 Duocort Pharma Ab Improved glucocorticoid therapy

Also Published As

Publication number Publication date
AU2011254959A1 (en) 2013-01-10
CO6660433A2 (en) 2013-04-30
EP2571505A1 (en) 2013-03-27
EP2571505B1 (en) 2016-07-06
WO2011144327A1 (en) 2011-11-24
CN102933218A (en) 2013-02-13
PE20131024A1 (en) 2013-10-10
MX2012013254A (en) 2013-01-24
CA2799820A1 (en) 2011-11-24
MX337429B (en) 2016-03-04
KR20130099815A (en) 2013-09-06
CL2012003152A1 (en) 2013-07-12
SG185457A1 (en) 2012-12-28
US20150209375A1 (en) 2015-07-30
US20130209565A1 (en) 2013-08-15
IL223000A0 (en) 2013-02-03
BR112012029466A2 (en) 2017-03-01
JP2013526552A (en) 2013-06-24

Similar Documents

Publication Publication Date Title
ZA201801246B (en) Xten conjugate compositions and methods of making same
IL253870B (en) Certain amino-pyrimidines and pharmaceutical compositions comprising them
HK1175947A1 (en) Pharmaceutical compositions and methods of making same
IL250259A0 (en) Compositions comprising ursolic acid and derivatives thereof and uses thereof
IL223000A0 (en) Posology and administration of glucocorticoid based compositions
EP2612655A4 (en) Liquid compositions of insoluble drugs and preparation methods thereof
EP2536756A4 (en) Hsa-related compositions and methods of use
EP2584897A4 (en) Resveratrol-containing compositions and methods of use
HRP20211969T1 (en) Pharmaceutical composition of carbetocin
PL2643419T3 (en) Compositions of chloro-trifluoropropene and hexafluorobutene
GB2478849A8 (en) Improved pharmaceutical compositions and methods of delivery
IL225227A0 (en) Fulvestrant compositions and methods of use
EP2596112A4 (en) Acetycysteine compositions and methods of use thereof
IL220715A0 (en) Nutritive compositions and methods of using same
EP2552447A4 (en) Stable pharmaceutical composition of imatinib
IL247929B (en) Stable sns-595 compositions and methods of preparation
IL224191A (en) Formulations of 14 -epi-analogues of vitamin d and cmc
IL219018A (en) Pharmaceutical compositions of radezolid and uses thereof
ZA201300041B (en) Methods and compositions of beneficiation
AU2010905320A0 (en) Methods and Preparation and Uses of Xanthorrhoeaceae Compositions